Along with mismatch repair deficiency and PD-L1 expression, well-established predictors of response to immune checkpoint blockers (ICBs), several studies have shown that greater tumor mutation burden (TMB) is associated with a greater likelihood of response of NSCLC to immunotherapy (Rizvi et al., 2015). This evidence concerns the gene CD274 and neoplasm.